Cargando…

Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience

OBJECTIVE: Atrial tachyarrhythmias (ATAs) lead to clinical deterioration and worsening heart failure (HF) in patients with acute decompensated HF (ADHF). We evaluated the effects of the ultrashort-acting intravenous β1-blocker landiolol on the heart rate, hemodynamics, and outcome in patients with A...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsui, Yuko, Suzuki, Atsushi, Shiga, Tsuyoshi, Arai, Kotaro, Hagiwara, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423156/
https://www.ncbi.nlm.nih.gov/pubmed/30810944
http://dx.doi.org/10.1007/s40801-019-0149-1
_version_ 1783404492915474432
author Matsui, Yuko
Suzuki, Atsushi
Shiga, Tsuyoshi
Arai, Kotaro
Hagiwara, Nobuhisa
author_facet Matsui, Yuko
Suzuki, Atsushi
Shiga, Tsuyoshi
Arai, Kotaro
Hagiwara, Nobuhisa
author_sort Matsui, Yuko
collection PubMed
description OBJECTIVE: Atrial tachyarrhythmias (ATAs) lead to clinical deterioration and worsening heart failure (HF) in patients with acute decompensated HF (ADHF). We evaluated the effects of the ultrashort-acting intravenous β1-blocker landiolol on the heart rate, hemodynamics, and outcome in patients with ATAs and ADHF. METHODS: A total of 67 consecutive hospitalized patients with ATAs and ADHF who were treated with landiolol (36 males, 67 ± 12 years) were included in this single-center retrospective study. The primary endpoints were changes in heart rate and systolic blood pressure from baseline during intravenous landiolol administration. The secondary endpoints included restoration of sinus rhythm and outcomes. RESULTS: The median maintenance dose of intravenous landiolol was 3.0 (range 1.0–12.0) μg/kg/min and the median treatment duration was 5 (range 1–24) days. Intravenous landiolol reduced heart rate (141 ± 17 beats/min at baseline to 99 ± 20 beats/min at 6 h, P < 0.001) without a marked reduction in blood pressure or deterioration of HF. During landiolol treatment, 15 (22%) patients had spontaneously restored sinus rhythm. Eight patients experienced in-hospital death, and 41 (69%) were discharged with sinus rhythm. During the follow-up of 16 ± 12 months, patients with sinus rhythm showed a lower frequency of rehospitalization due to worsening HF than patients with ATAs (5/41 vs. 7/18, P = 0.019). CONCLUSIONS: Our results showed that intravenous landiolol reduces the heart rate without markedly decreasing blood pressure in patients with ATAs and ADHF. Approximately 70% of the discharged patients were in sinus rhythm, and these patients showed a lower frequency of rehospitalization due to worsening HF (UMIN-CTR no. UMIN000033650).
format Online
Article
Text
id pubmed-6423156
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-64231562019-04-05 Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience Matsui, Yuko Suzuki, Atsushi Shiga, Tsuyoshi Arai, Kotaro Hagiwara, Nobuhisa Drugs Real World Outcomes Original Research Article OBJECTIVE: Atrial tachyarrhythmias (ATAs) lead to clinical deterioration and worsening heart failure (HF) in patients with acute decompensated HF (ADHF). We evaluated the effects of the ultrashort-acting intravenous β1-blocker landiolol on the heart rate, hemodynamics, and outcome in patients with ATAs and ADHF. METHODS: A total of 67 consecutive hospitalized patients with ATAs and ADHF who were treated with landiolol (36 males, 67 ± 12 years) were included in this single-center retrospective study. The primary endpoints were changes in heart rate and systolic blood pressure from baseline during intravenous landiolol administration. The secondary endpoints included restoration of sinus rhythm and outcomes. RESULTS: The median maintenance dose of intravenous landiolol was 3.0 (range 1.0–12.0) μg/kg/min and the median treatment duration was 5 (range 1–24) days. Intravenous landiolol reduced heart rate (141 ± 17 beats/min at baseline to 99 ± 20 beats/min at 6 h, P < 0.001) without a marked reduction in blood pressure or deterioration of HF. During landiolol treatment, 15 (22%) patients had spontaneously restored sinus rhythm. Eight patients experienced in-hospital death, and 41 (69%) were discharged with sinus rhythm. During the follow-up of 16 ± 12 months, patients with sinus rhythm showed a lower frequency of rehospitalization due to worsening HF than patients with ATAs (5/41 vs. 7/18, P = 0.019). CONCLUSIONS: Our results showed that intravenous landiolol reduces the heart rate without markedly decreasing blood pressure in patients with ATAs and ADHF. Approximately 70% of the discharged patients were in sinus rhythm, and these patients showed a lower frequency of rehospitalization due to worsening HF (UMIN-CTR no. UMIN000033650). Springer International Publishing 2019-02-27 /pmc/articles/PMC6423156/ /pubmed/30810944 http://dx.doi.org/10.1007/s40801-019-0149-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Matsui, Yuko
Suzuki, Atsushi
Shiga, Tsuyoshi
Arai, Kotaro
Hagiwara, Nobuhisa
Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
title Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
title_full Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
title_fullStr Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
title_full_unstemmed Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
title_short Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
title_sort effects of intravenous landiolol on heart rate and outcomes in patients with atrial tachyarrhythmias and acute decompensated heart failure: a single-center experience
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423156/
https://www.ncbi.nlm.nih.gov/pubmed/30810944
http://dx.doi.org/10.1007/s40801-019-0149-1
work_keys_str_mv AT matsuiyuko effectsofintravenouslandiololonheartrateandoutcomesinpatientswithatrialtachyarrhythmiasandacutedecompensatedheartfailureasinglecenterexperience
AT suzukiatsushi effectsofintravenouslandiololonheartrateandoutcomesinpatientswithatrialtachyarrhythmiasandacutedecompensatedheartfailureasinglecenterexperience
AT shigatsuyoshi effectsofintravenouslandiololonheartrateandoutcomesinpatientswithatrialtachyarrhythmiasandacutedecompensatedheartfailureasinglecenterexperience
AT araikotaro effectsofintravenouslandiololonheartrateandoutcomesinpatientswithatrialtachyarrhythmiasandacutedecompensatedheartfailureasinglecenterexperience
AT hagiwaranobuhisa effectsofintravenouslandiololonheartrateandoutcomesinpatientswithatrialtachyarrhythmiasandacutedecompensatedheartfailureasinglecenterexperience